Skip to content
Screener

Arcus Biosciences RCUS Q1 2026 earnings

Reported May 5, 2026 · After market close

Revenue$17.0MMiss by $12.5M
EPS-$1.02Miss by $0.10
Revenue estimate$29.5M
EPS estimate-$0.92

Next report

Oct 27, 2026 (in a month)
Revenue estimate$11.0M
EPS estimate-$0.89

Financials

Q1 2026

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.71B+226%
Enterprise value$2.62B+275%
P/S11.5×+5.6×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%—

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio4×-1.3×

Segments

By segment

See full
Reportable segment$17.0M-39.3%

By product

See full
R&D services$2.0M0.0%

FAQ

When did Arcus Biosciences report Q1 2026 earnings?
Arcus Biosciences (RCUS) reported Q1 2026 earnings on May 5, 2026 after market close.
What were Arcus Biosciences's Q1 2026 revenue and EPS?
Arcus Biosciences reported revenue of $17.0M and eps of $-1.02 for Q1 2026.
Did Arcus Biosciences beat estimates in Q1 2026?
Revenue missed the consensus estimate of $29.5M by $12.5M. EPS missed the consensus estimate of $-0.92 by $0.10.
How did Arcus Biosciences's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 39.3% from $28.0M a year earlier and eps grew 10.5% from $-1.14.
Where can I find Arcus Biosciences's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001724521-26-000032) and the 10-Q periodic report (0001724521-26-000034) directly on SEC EDGAR. The filing index links above go to sec.gov.